CLINICAL_TRIALS
trial_result
· 2015-07-01
Clinical Trial Update: Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma [Phase 2]
Summary
A Phase 2 trial evaluating MGCD0103 (mocetinostat) given three times weekly in patients with relapsed and refractory lymphoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Mirati Therapeutics Inc. | Conditions: Lymphoma | Phase 2 | Status: COMPLETED